A severe case of chronic infantile neurologic, cutaneous, articular syndrome treated with biologic agents

Arthritis and Rheumatism

Volumn 54, Issue 7, 2006, Pages 2314-2320

  Matsubara, Tomoyo ^a   Hasegawa, Masanari ^a   Shiraishi, Masahiro ^a   Hoffman, Hal M ^b   Ichiyama, Takashi ^a   Tanaka, Takeo ^c   Ueda, Haruo ^c   Ishihara, Tokuhiro ^a   Furukawa, Susumu ^a  

^a YAMAGUCHI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID A PROTEIN; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; CRYOPYRIN; CYTOKINE RECEPTOR ANTAGONIST; ETANERCEPT; IMMUNOGLOBULIN; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 6 RECEPTOR ANTIBODY; PROTEIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; AUTOINFLAMMATORY DISEASE; CASE REPORT; CINCA SYNDROME; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; FEVER; GENE MUTATION; HUMAN; INFLAMMATION; INTERSTITIAL PNEUMONIA; IRRITABILITY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIRHEUMATIC AGENTS; AUTOIMMUNE DISEASES; CARRIER PROTEINS; CENTRAL NERVOUS SYSTEM DISEASES; CYTOKINES; EXANTHEMA; FEVER; HUMANS; IMMUNOGLOBULIN G; INFANT; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; JOINT DISEASES; MALE; MUTATION; RECEPTORS, INTERLEUKIN-6; RECEPTORS, TUMOR NECROSIS FACTOR; SIALOGLYCOPROTEINS; SYNDROME;

EID: 33745880105     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.21965     Document Type: Article

References (20)

1. Hassink SG, Goldsmith DP. Neonatal onset multisystem inflammatory disease. Arthritis Rheum 1983;26:668-73.
2. Prieur AM, Griscelli C, Lampert F, Truckenbrodt H, Guggenheim MA, Lovell DJ, et al. A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome: a specific entity analysed in 30 patients. Scand J Rheumatol Suppl 1987;66:57-68.
3. Hull KM, Shoham N, Chae JJ, Aksentijevich I, Kastner DL. The expanding spectrum of systemic autoinflammatory disorders and their rheumatic manifestations. Curr Opin Rheumatol 2003;15:61-9.
4. Aksentijevich I, Nowak M, Mallah M, Chae JJ, Watford WT, Hofmann SR, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease: a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002;46:3340-8.
5. Feldmann J, Prieur AM, Quartier P, Berquin P, Certain S, Cortis E, et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet 2002;71:198-203.
6. Manji GA, Wang L, Geddes BJ, Brown M, Merriam S, Al-Garawi A, et al. PYPAF1, a pyrin-containing Apaf1-like protein that assembles with ASC and regulates activation of NF-κB. J Biol Chem 2002;277:11570-5.
7. Hoffman HM, Mueller JL, Broide DH, Wanderer AA, Kolodner RD. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001;29:301-5.
8. Ichiyama T, Yoshitomi T, Nishikawa M, Fujiwara M, Matsubara T, Hayashi T, et al. NF-κB activation in peripheral blood monocytes/macrophages and T cells during acute Kawasaki disease. Clin Immunol 2001;99:373-7.
9. Janssen R, Verhard E, Lankester A, Ten Cate R, van Dissel JT. Enhanced interleukin-1β and interleukin-18 release in a patient with chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 2004;50:3329-33.
10. Singer NG, Scalzi LV. Remittive agents in pediatric rheumatology. Curr Opin Rheumatol 2004;16:571-6.
11. Granel B, Serratrice J, Disdier P, Weiller PJ. Dramatic improvement with anakinra in a case of chronic infantile neurological cutaneous and articular (CINCA) syndrome. Rheumatology (Oxford) 2005;44:689-90.
12. Lovell DJ, Bowyer SL, Solinger AM. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal-onset multisystem inflammatory disease. Arthritis Rheum 2005;52:1283-6.
13. Federico G, Rigante D, Pugliese AL, Ranno O, Catania S, Stabile A. Etanercept induces improvement of arthropathy in chronic infantile neurological cutaneous articular syndrome. Scand J Rheumatol 2003;32:312-4.
14. Iwamoto M, Nara H, Hirata D, Minota S, Nishimoto N, Yoshizaki K. Humanized monoclonal anti-interleukin-6 receptor antibody for treatment of intractable adult-onset Still's disease. Arthritis Rheum 2002;46:3388-9.
15. Choy EH, Isenberg DA, Garrood T, Farrow S, Ioannou Y, Bird H, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum 2002;46:3143-50.
16. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:1761-9.
17. Nishimoto N, Sasai M, Shima Y, Nakagawa M, Matsumoto T, Shirai T, et al. Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 2000;95:56-61.
18. Yokota S, Miyamae T, Imagawa T, Iwata N, Katakura S, Mori M, et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum 2005;52:818-25.
19. Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 2005;34:819-36.
20. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004;116:305-11.